scholarly journals GlicoPro, Novel Standardized and Sterile Snail Mucus Extract for Multi-Modulative Ocular Formulations. New Perspective in Dry Eye Disease Management

Pharmaceutics ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2139
Author(s):  
Rita Mencucci ◽  
Giovanni Strazzabosco ◽  
Virginia Cristofori ◽  
Andrea Alogna ◽  
Daria Bortolotti ◽  
...  
Keyword(s):  
Dry Eye ◽  
Sodium Hyaluronate ◽  
Ophthalmic Solution ◽  
Dry Eye Disease ◽  
Mass Spectrometry Analysis ◽  
Corneal Epithelial Cell ◽  
Eye Disease ◽  
Corneal Cells ◽  
Anti Inflammatory

This study aimed to evaluate the mucoadhesive and regenerative properties of a novel lubricating multimolecular ophthalmic solution (GlicoPro®) extracted from snail mucus and its potential anti-inflammatory and analgesic role in the management of dry eye disease (DED). GlicoPro bio-adhesive efficacy was assessed using a lectin-based assay, and its regenerative properties were studied in a human corneal epithelial cell line. In vitro DED was induced in human corneal tissues; the histology and mRNA expression of selected genes of inflammatory and corneal damage biomarkers were analyzed in DED tissues treated with GlicoPro. A higher percentage of bio-adhesivity was observed in corneal cells treated with GlicoPro than with sodium hyaluronate-based compounds. In the scratch test GlicoPro improved in vitro corneal wound healing. Histo-morphological analysis revealed restoration of cellular organization of the corneal epithelium, microvilli, and mucin network in DED corneal tissues treated with GlicoPro. A significant reduction in inflammatory and ocular damage biomarkers was observed. High-performance liquid chromatography-mass spectrometry analysis identified an endogenous opioid, opiorphin, in the peptide fraction of GlicoPro. In conclusion, GlicoPro induced regeneration and bio-adhesivity in corneal cells; moreover, considering its anti-inflammatory and analgesic properties, this novel ophthalmic lubricating solution may be an innovative approach for the management of DED.

scholarly journals Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation

Pharmaceutics ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 1698
Author(s):  
Ana López-Machado ◽  
Natalia Díaz-Garrido ◽  
Amanda Cano ◽  
Marta Espina ◽  
Josefa Badia ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ex Vivo ◽  
Visual Disturbance ◽  
Nasolacrimal Duct ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Lipid Film ◽  
Anti Inflammatory

Dry eye disease (DED) is a high prevalent multifactorial disease characterized by a lack of homeostasis of the tear film which causes ocular surface inflammation, soreness, and visual disturbance. Conventional ophthalmic treatments present limitations such as low bioavailability and side effects. Lactoferrin (LF) constitutes a promising therapeutic tool, but its poor aqueous stability and high nasolacrimal duct drainage hinder its potential efficacy. In this study, we incorporate lactoferrin into hyaluronic acid coated liposomes by the lipid film method, followed by high pressure homogenization. Pharmacokinetic and pharmacodynamic profiles were evaluated in vitro and ex vivo. Cytotoxicity and ocular tolerance were assayed both in vitro and in vivo using New Zealand rabbits, as well as dry eye and anti-inflammatory treatments. LF loaded liposomes showed an average size of 90 nm, monomodal population, positive surface charge and a high molecular weight protein encapsulation of 53%. Biopharmaceutical behaviour was enhanced by the nanocarrier, and any cytotoxic effect was studied in human corneal epithelial cells. Developed liposomes revealed the ability to reverse dry eye symptoms and possess anti-inflammatory efficacy, without inducing ocular irritation. Hence, lactoferrin loaded liposomes could offer an innovative nanotechnological tool as suitable approach in the treatment of DED.

Demonstration of Efficacy in the Treatment of Dry Eye Disease with 0.18% Sodium Hyaluronate Ophthalmic Solution (Vismed, Rejena)

2010 ◽  
Vol 149 (4) ◽  
pp. 594-601 ◽  
Author(s):  
Roger Vogel ◽  
R. Stephens Crockett ◽  
Neal Oden ◽  
Terry W. Laliberte ◽  
Luis Molina
Keyword(s):  
Dry Eye ◽  
Sodium Hyaluronate ◽  
Ophthalmic Solution ◽  
Dry Eye Disease ◽  
Eye Disease

scholarly journals Lifitegrast: a novel drug for patients with dry eye disease

2019 ◽  
Vol 11 ◽  
pp. 251584141987036 ◽  
Author(s):  
Stacy L. Haber ◽  
Vera Benson ◽  
Casey J. Buckway ◽  
Jennifer M. Gonzales ◽  
David Romanet ◽  
...  
Keyword(s):  
Dry Eye ◽  
English Language ◽  
Ophthalmic Solution ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Inadequate Response ◽  
Efficacy And Safety ◽  
Inclusion Phase

The objective of this article is to review the pharmacology, efficacy, and safety of lifitegrast and determine its role relative to other agents in the management of dry eye disease. A PubMed search (1946 to December 2018) using the terms lifitegrast and SAR 1118 was conducted to identify relevant articles. In vitro or in vivo evaluations of lifitegrast published in the English language were eligible for inclusion. Phase II and III trials were selected for review of efficacy and safety. Four randomized controlled trials evaluated the efficacy and safety of lifitegrast 0.5% ophthalmic solution for 12 weeks, and 1 additional trial assessed safety for 1 year. In a majority of the trials, lifitegrast caused statistically significant improvements in inferior corneal fluorescein staining scores and eye dryness scores. The most common adverse effects were eye irritation, dysgeusia, and reduced visual acuity, and most were mild to moderate in severity. Lifitegrast has a novel mechanism of action and is safe and effective for the treatment of dry eye disease. At this time, lifitegrast may be considered as an option for patients who have an inadequate response to artificial tears.

scholarly journals Aucuba japonica Extract and Aucubin Prevent Desiccating Stress-Induced Corneal Epithelial Cell Injury and Improve Tear Secretion in a Mouse Model of Dry Eye Disease

Molecules ◽  
2018 ◽  
Vol 23 (10) ◽  
pp. 2599 ◽  
Author(s):  
Wan Kang ◽  
Eunsoo Jung ◽  
Junghyun Kim
Keyword(s):  
Dry Eye ◽  
Bioactive Compound ◽  
Dry Eye Disease ◽  
Terminal Deoxynucleotidyl Transferase ◽  
Corneal Epithelial Cell ◽  
Eye Disease ◽  
Tunel Staining ◽  
Therapeutic Effects ◽  
Aucuba Japonica ◽  
Inflammatory Molecules

Dry eye disease is affected by a broad range of causes such as age, lifestyle, environment, medication and autoimmune diseases. These causes induce tear instability that activates immune cells and promotes expression of inflammatory molecules. In this study, we investigated the therapeutic effects of an ethanolic extract of Aucuba japonica (AJE) and its bioactive compound, aucubin, on dry eye disease. The human corneal cells were exposed to desiccation stress induced by exposing cells to air, so that viability was decreased. On the other hand, pre-treatment of AJE and aucubin restored cell survival rate depending on the dose under the dry condition. This result was confirmed again by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. The mRNA expression of inflammatory molecules was reduced by the pretreatment of AJE and aucubin under the dry state. The therapeutic effects of AJE and aucubin were examined in the animal model for dry eye induced by unilateral excision of the exorbital lacrimal gland. Declined tear volumes and corneal irregularity in the dry eye group were fully recovered by the administration of AJE and aucubin. The apoptotic cells on the cornea were also decreased by AJE and aucubin. Therefore, this study suggests that administration of AJE can be a novel therapeutic for dry eye disease and that the pharmacological activities of AJE may be in part due to its bioactive compound, aucubin.

scholarly journals Cyclosporine use in “dry eye” syndrome

2019 ◽  
Vol 12 (3) ◽  
pp. 75-82
Author(s):  
Inna A. Riks
Keyword(s):  
Literature Review ◽  
Dry Eye ◽  
Dry Eye Disease ◽  
Dry Eye Syndrome ◽  
Eye Disease ◽  
Anti Inflammatory

This literature review focuses on the need for anti-inflammatory therapy for dry eye disease (DED). Causes of development and mechanisms of pathogenesis of DED are presented. Principles of action of various groups of anti-inflammatory medications, as well as recommendations for cyclosporine use of are described. The results of studies on cyclosporine efficacy are highlighted, principles of cyclosporin prescription in DED are listed.

scholarly journals New Therapeutic Strategy and Innovative Lubricating Ophthalmic Solution in Minimizing Dry Eye Disease Associated with Cataract Surgery: A Randomized, Prospective Study

2020 ◽  
Vol 37 (4) ◽  
pp. 1664-1674 ◽  
Author(s):  
Paolo Fogagnolo ◽  
Eleonora Favuzza ◽  
Daniele Marchina ◽  
Michela Cennamo ◽  
Roberto Vignapiano ◽  
...  
Keyword(s):  
Prospective Study ◽  
Cataract Surgery ◽  
Dry Eye ◽  
Therapeutic Strategy ◽  
Ophthalmic Solution ◽  
Dry Eye Disease ◽  
Eye Disease
Sign in / Sign up

Export Citation Format

Share Document